The funding round was backed by a distinguished group of investors, including IDG Capital and SongQing Capital. Existing investors — WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi — also contributed to the round. The robust involvement from both new and current investors highlights widespread confidence in D3 Bio's innovative pipeline and its global development strategy.

 

Proceeds from this financing will primarily support the planned global Phase III pivotal programme for the startup's lead asset, elisrasib (D3S-001). These pivotal trials will assess elisrasib as both a monotherapy and in combination therapies for KRAS G12C-mutant cancers across key countries and regions, including the United States, China, and the European Union, to facilitate global regulatory submissions.

 

Furthermore, the funding will facilitate ongoing development of D3 Bio's comprehensive pipeline of targeted and immuno-oncology programmes, which are centred on innovative mechanisms with first-in-class or best-in-class potential.